Mepolizumab
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Mepolizumab: Thrombocytopenia due to immune destruction
One-Sentence Summary
Mepolizumab is an anti-IL-5 monoclonal antibody, originally associated with eosinophilic pneumonia and pulmonary eosinophilia. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, but the current evidence is very limited: 0 clinical trials and 1 publication (a case report) support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 0.9966 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, mepolizumab is an anti-IL-5 monoclonal antibody that depletes eosinophils. Its role in eosinophil-driven conditions such as eosinophilic pneumonia is consistent with this mechanism.
The link to immune-mediated thrombocytopenia is weak and indirect. The only linked publication is a case report in which a steroid-resistant hypereosinophilic immune disorder, accompanied by a mixed thrombotic microangiopathy, improved with mepolizumab plus concomitant therapy. This suggests that eosinophil-driven immune dysregulation may coexist with immune-mediated cytopenias.
There is no direct evidence that IL-5 blockade treats immune thrombocytopenia itself. Its pathogenesis is mainly autoantibody-mediated platelet destruction and impaired platelet production. The high TxGNN score is a computational prediction and should not be read as clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case report | Blood Cells Mol Dis | A steroid-resistant hypereosinophilic immune disorder resolved with mepolizumab, with concurrent improvement of a mixed thrombotic microangiopathy. Single patient; indirect relevance to immune thrombocytopenia. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02530821 | NUCALA | Not specified | Not specified |
| 02492997 | NUCALA | Not specified | Not specified |
| 02492989 | NUCALA | Not specified | Not specified |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found, and no contraindication records were found in the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a high model score and a single indirect case report. There are no clinical trials, and there is no established mechanistic link between IL-5 blockade and immune-mediated platelet destruction. Mepolizumab is marketed in Canada, but for other uses.
To proceed, the following is needed:
- Mechanism of action data, to allow a proper mechanistic assessment
- Health Canada package insert warnings, contraindications and approved indication text, which are required before safety screening
- Preclinical or mechanistic studies showing a role for IL-5 or eosinophils in immune thrombocytopenia
- Observational data or clinical trials in patients with immune thrombocytopenia, particularly those with coexisting hypereosinophilia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.